5 Healthcare and Biotech Stocks to Buy Amid Monkeypox Threat

2. Moderna, Inc. (NASDAQ:MRNA)

Number of Hedge Fund Holders: 41

Moderna, Inc. (NASDAQ:MRNA), a leading healthcare company, announced on May 24 that it is working on a vaccine to treat monkeypox. Back in May 2022, the company was running vaccine tests against monkeypox at a pre-clinical level. On August 3, Moderna, Inc. (NASDAQ:MRNA) announced that its pre-clinical trials of a monkeypox vaccine are still ongoing and that the company is simultaneously focusing on its vaccines against COVID-19. As of August 5, Moderna, Inc. (NASDAQ:MRNA) has returned 21.87% to investors over the past six months.

On August 3, Moderna, Inc. (NASDAQ:MRNA) reported earnings for the fiscal second quarter of 2022. The company reported earnings per share of $5.24 and beat EPS estimates by $0.75. The company reported a revenue of $4.75 billion, up 9.07% year over year, and beat revenue consensus by $794.40 million.

At the end of Q1 2022, 41 hedge funds were bullish on Moderna, Inc. (NASDAQ:MRNA) and held stakes worth $3.79 billion in the company. This is compared to 43 positions in the previous quarter with stakes worth $3.88 billion.

As of March 31, Coatue Management is the largest shareholder in Moderna, Inc. (NASDAQ:MRNA) and holds a stake worth $1.19 billion in the company. The investment covers 8.72% of Coatue Management’s 13F portfolio.